Article info

other Versions

PDF
The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review

Authors

  1. Correspondence to Dr Carol Dryden, Department of Paediatrics, Wishaw General Hospital, Netherton Street, Wishaw ML2 0DP, UK; carol.dryden{at}lanarkshire.scot.nhs.uk
View Full Text

Citation

Dryden C, Wilkinson J, Young D on behalf of the Scottish Paediatric Cystic Fibrosis Managed Clinical Network (SPCFMCN), et al
The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review

Publication history

  • Received December 29, 2015
  • Revised May 13, 2016
  • Accepted May 16, 2016
  • First published June 10, 2016.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.